SGLT2 inhibitor

Empagliflozin

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

EMPAGLIFLOZIN

Agent: empagliflozin
Dosing: fixed
Mechanism: Sodium glucose cotransporter 2 inhibitor
Trials: 3
Participants in these arms: 12

Molecule level node. Arms of different doses of this comparator within a trial are combined into one arm.

Effects across outcomes

Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.

Condition	Outcome	Window	Versus	Effect (95% CrI)	SUCRA
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.93 (-1.52 to -0.30)	0.54
Type 2 diabetes (adults)	HbA1c change	weeks 20 to 36 (target week 26)	Placebo	MD -0.84 (-1.43 to -0.23)	0.50
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD 0.63 (0.02 to 1.28)	0.13
Type 2 diabetes (adults)	HbA1c change	weeks 36 to 64 (target week 52)	Placebo	MD 0.20 (-1.04 to 1.53)	0.27
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -1.50 (-6.58 to 3.87)	0.52
Type 2 diabetes (adults)	Body weight change in kilograms (diabetes)	weeks 36 to 64 (target week 52)	Placebo	MD -0.54 (-7.14 to 6.28)	0.49
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 2.20 (0.23 to 26.89)	0.38
Type 2 diabetes (adults)	Level 2 or 3 hypoglycemia (participants)	longest follow-up	Placebo	HR 2.03 (0.21 to 26.09)	0.43
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD -1.20 (-9.82 to 7.61)	0.78
Type 2 diabetes (adults)	Systolic blood pressure change	weeks 36 to 64 (target week 52)	Placebo	MD -5.73 (-13.94 to 2.72)	0.90
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 0.54 (0.01 to 42.90)	0.58
Type 2 diabetes (adults)	Serious adverse events	longest follow-up	Placebo	HR 0.55 (0.01 to 43.89)	0.60
Type 1 diabetes	HbA1c change	weeks 12 to 40 (target week 26)	Placebo	MD -0.24 (-1.29 to 0.79)	0.61
Type 1 diabetes	HbA1c change	weeks 12 to 40 (target week 26)	Placebo	MD -0.25 (-1.38 to 0.92)	0.54
Type 1 diabetes	Total daily insulin dose change	weeks 12 to 40 (target week 26)	Placebo	MD -0.20 (-1.16 to 0.76)	0.57
Type 1 diabetes	Total daily insulin dose change	weeks 12 to 40 (target week 26)	Placebo	MD -0.21 (-1.19 to 0.76)	0.58

Empagliflozin

Related

Effects across outcomes

Trials